Glazer A A, Novick A C
Department of Urology, Cleveland Clinic Foundation, Ohio 44195, USA.
J Urol. 1996 Feb;155(2):448-50.
Renal cell carcinoma extends into the inferior vena cava in 4 to 10% of patients and it is believed that the cephalad extent of inferior vena caval involvement is inversely correlated with survival. We evaluated this issue further.
From June 1984 to August 1993, 18 patients underwent surgical treatment for localized renal cell carcinoma and an inferior vena caval thrombus extending into the right atrium. One patient had a contralateral adrenal metastasis at operation. All patients underwent complete tumor excision with radical nephrectomy and inferior vena caval thrombectomy using adjunctive cardiopulmonary bypass and deep hypothermic circulatory arrest. Pathological study indicated no renal capsular penetration of renal cell carcinoma in 10 patients and perinephric fat involvement in 8.
The overall and cancer-specific 5-year survival rates were 56.6% and 60.2%, respectively. Eight patients (45%) were free of malignancy at a mean of 71.6 months. One patient was alive with metastatic disease 15 months postoperatively. There was 1 operative death, while 8 patients died of metastatic renal cell carcinoma at a mean of 18.8 months postoperatively. Mean postoperative survival was significantly improved in patients with no renal capsular penetration by tumor compared to those with perinephric fat involvement (58.1 versus 19.7 months, p = 0.035).
Long-term survival after surgical treatment is possible in patients with localized renal cell carcinoma extending into the right atrium. In patients with localized renal cell carcinoma and an inferior vena caval tumor thrombus the cephalad extent of inferior vena caval involvement does not appear to be prognostically important.
4%至10%的患者肾细胞癌会侵犯下腔静脉,据信下腔静脉受累的头端范围与生存率呈负相关。我们进一步评估了这个问题。
1984年6月至1993年8月,18例局限性肾细胞癌合并下腔静脉血栓延伸至右心房的患者接受了手术治疗。1例患者术中发现对侧肾上腺转移。所有患者均接受了根治性肾切除术及下腔静脉血栓切除术,术中采用体外循环和深低温停循环辅助。病理研究显示,10例患者肾细胞癌未穿透肾包膜,8例患者肾周脂肪受累。
总体5年生存率和癌症特异性5年生存率分别为56.6%和60.2%。8例患者(45%)平均在71.6个月时无恶性肿瘤。1例患者术后15个月带转移瘤存活。手术死亡1例,8例患者术后平均18.8个月死于转移性肾细胞癌。与肾周脂肪受累的患者相比,肿瘤未穿透肾包膜的患者术后平均生存期显著延长(58.1个月对19.7个月,p = 0.035)。
局限性肾细胞癌延伸至右心房的患者手术治疗后有可能长期存活。对于局限性肾细胞癌合并下腔静脉肿瘤血栓的患者,下腔静脉受累的头端范围似乎对预后并不重要。